AMBIRIX

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug AMBIRIX contains a combination of these active pharmaceutical ingredients (APIs):

1	Hepatitis A, inactivated vaccine
	Inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, highly purified, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulphate.
	Read more about Hepatitis A, inactivated vaccine
2	Hepatitis B, purified antigen
	Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
	Read more about Hepatitis B, purified antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMBIRIX Suspension for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BC20	Combinations	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1208922, 1208933, 1208944
GB	Medicines & Healthcare Products Regulatory Agency	129520
LT	Valstybinė vaistų kontrolės tarnyba	1027357, 1027358, 1027359, 1027360, 1027361
NL	Z-Index G-Standaard	14816288
NL	Z-Index G-Standaard, PRK	48933
PL	Rejestru Produktów Leczniczych	100127298